Centrus Energy is a trusted supplier of nuclear fuel and services for the nuclear power industry. Centrus provides value to its utility customers through the reliability and diversity of its supply sources – helping them meet the growing need for clean, affordable, carbon-free electricity. Since 1998, the Company has provided its utility customers with more than 1,750 reactor years of fuel, which is equivalent to 7 billion tons of coal. With world-class technical and engineering capabilities, Centrus is also advancing the next generation of centrifuge technologies so that America can restore its domestic uranium enrichment capability in the future. Find out more at www.centrusenergy.com.

Daikin has been a world leader in the development, manufacture and sales of fluoropolymers and chemistry since 1924 . Headquartered in Osaka, Japan, Daikin is renowned for innovation, quality and commitment. As the world changes, Daikin is meeting the challenges with technology that makes a difference. We have in the forefront of the fluorocarbon industry is not just constant innovation in the products we develop, but the service and support behind them. Daikin’s fluoropolymers and chemicals, with their wide range of unique properties and Daikin’s products area ideally suited for use in aerospace, architecture, automotive, consumer cookware, energy storage, filtration, home goods, industry, medical, nonwovens, optics & displays, paper & packaging, oil & gas, renewable energy, semiconductor, textile & fabric treatments and wire & cable.

Since 1949, Combe brands have been part of people’s most personal moments. When a man faces his first gray hairs in the mirror — or a woman wonders how to care for the most intimate area of her body — Combe brands are here to help people feel like themselves again: Confident. Comfortable. Looking and feeling their best. We put people’s personal care needs at the center of every thing we do. These aren’t niche needs. They are universal needs, but often kept private. We respect that. At Combe, instead of shying away from these very personal Personal Care problems, we aim to solve them. We believe that’s the right thing to do for people and the smart thing to do for business. Remaining true to our consumer-oriented innovation and marketing platform, Combe markets a portfolio of established brands that include Just for Men, Vagisil, and Sea-Bond in major international markets and Aqua Velva, Lectric Shave, and Brylcreem in the U.S. and Canada. Building upon its success in the United States, Combe has grown steadily in international markets over the last almost four decades, and generates approximately one-third of its revenues from markets outside of the U.S. and Canada including the United Kingdom, Spain, Italy, Australia, Canada, Mexico, and Brazil. The company has transitioned to its third generation of Combe family leadership, under the direction of Keech Combe Shetty and Akshay Shetty.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD). It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III

Renaissance is a US-based contract development and manufacturing organization (CDMO) for pharmaceutical and biotech companies. With over 20 years of experience in nasal sprays and sterile injectable dosage forms, we have an unparalleled track record of helping our clients from development through to commercial launch. Core Capabilities: - Aseptic fill-finish development and manufacturing (vials) - Unit-dose and bi-dose nasal spray development and manufacturing - Preserved and Non-preserved multi-dose nasal spray development and manufacturing - Analytical development & testing services - Spray characterization development & testing services - Formulation development & optimization - DEA Schedule I-V products From early-stage development through final production, Renaissance has the expertise and resources you need for success. Visit renpharm.com to learn more.

USALCO is the premier manufacturer of various aluminum-based chemicals, such as aluminum sulfate, sodium aluminate, polyaluminum chloride, aluminum chlorohydrate, and aluminum chloride, to industrial and municipal markets. USALCO’s Polyaluminum Chloride (PACL) products, DelPAC® and UltraPAC®, have become the coagulants of choice in well over 1,000 water treatment applications throughout the US. USALCO’s research and development staff is committed to continuously innovating new coagulant chemistry to address the ever-changing regulatory landscape. Coupled with our on-site application expertise, USALCO is uniquely positioned to meet the increasing customer demand for improved treatment results at a lower total cost. Our company headquarters is in Baltimore, Maryland which is also the site of the largest aluminum coagulant manufacturing plant in North America. USALCO operates at 31 facilities throughout the United States.

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

SK Life Science, Inc., a U.S. subsidiary of SK Biopharmaceuticals, is committed to accelerating the development of innovative treatments for central nervous system (CNS) disorders and oncology. Both companies are a part of SK Group, one of the largest conglomerates in Korea, a global leader in energy, chemical, semiconductor and telecommunications industries, and one of TIME’s 100 Most Influential Companies of 2023. SK Life Science, Inc., is headquartered in Paramus, New Jersey. SK Life Science and SK Biopharmaceuticals have eight compounds in development globally for the treatment of CNS disorders including epilepsy, attention-deficit hyperactivity disorder, schizophrenia, bipolar disorder, and oncology among others. For more information, please visit https://www.sklifescienceinc.com/innovation/#/pipeline. View our community guidelines here: bit.ly/447WI1A

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.